KANSAS CITY, Kan., Jan. 29, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing or acquisition, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced the upsizing and pricing of its previously announced public offering. The size of the offering has been increased from 5,500,000 shares of common stock to 6,500,000 shares of common stock at a price to the public of $19.00 per share. A total of 5,000,000 shares are being offered by Aratana Therapeutics, and a total of 1,500,000 shares are being offered by certain selling stockholders. The Company has granted the underwriters a 30-day option to purchase up to 150,000 shares of common stock and a selling stockholder has also granted the underwriters a 30-day option to purchase up to 825,000 additional shares of common stock.
Jefferies LLC, Barclays, and William Blair are acting as joint book-running managers for the offering. JMP Securities and Craig-Hallum Capital Group are acting as co-managers.
A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful.
The offering is being made only by means of a written prospectus forming part of the effective registration statement. Copies of the prospectus related to the offering may be obtained, when available, from Jefferies LLC, c/o Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th FL, New York, NY 10022, Prospectus_Department@Jefferies.com, (877) 547-6340; or Barclays, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, barclaysprospectus@broadridge.com, (888) 603-5847; or William Blair, Attention: Prospectus Department, 222 West Adams Street, Chicago, IL 60606, prospectus@williamblair.com, telephone: (800) 621-0687.
Contacts:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.
jdrumm@tiberend.com; (212) 375-2664
Andrew Mielach
amielach@tiberend.com; (212) 375-2694
SOURCE Aratana Therapeutics, Inc.